IL13 and glioblastoma: MV was also designed to express interleukin-13 (IL-13) directed to the IL-13Rα2 receptor on glioblastoma (GBM) cells, or the single-chain antibody versus the vIII variant of epidermal growth factor receptor (EGFRvIII) [65,66,67].